Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.82 |
| ▸ | CNR1 | P21554 | 15/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | MTOR | P42345 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2833584 | 0.89 | CNR2 (0.85) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL29448220 | 0.87 | CNR2 (1.00) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL430254 | 0.87 | CNR2 (1.00) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL29426317 | 0.87 | CNR2 (1.00) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL29835924 | 0.87 | CNR2 (1.00) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL10068287 | 0.84 | CNR2 (0.71) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL10068288 | 0.84 | CNR2 (0.71) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL10068292 | 0.83 | CNR2 (0.85) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL15995557 | 0.81 | CNR2 (0.82) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL15995554 | 0.80 | CNR2 (0.80) | CNR2CNR1TP53CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9155797-B2 | Oligomer-cannabinoid conjugates | NEKTAR THERAPEUTICS (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140329895-A1 | OLIGOMER-CANNABINOID CONJUGATES | NEKTAR THERAPEUTICS | 2014-11-06 | — | — | US | disclosed |
| US-8829043-B2 | Oligome-cannabinoid conjugates | NEKTAR THERAPEUTICS (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120022063-A1 | Oligomer-Cannabinoid Conjugates | NEKTAR THERAPEUTICS (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2009099670-A2 | OLIGOMER-CANNABINOID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329895-A1 | OLIGOMER-CANNABINOID CONJUGATES | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885TP53 4737/4885 |
| US-20120022063-A1 | Oligomer-Cannabinoid Conjugates | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885TP53 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.